JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB166020

Recombinant Human YTHDF3 protein

Be the first to review this product! Submit a review

|

(1 Publication)

Recombinant Human YTHDF3 protein is a Human Full Length protein, in the 1 to 585 aa range, expressed in Wheat germ, suitable for ELISA, WB.

View Alternative Names

YTH domain-containing family protein 3, DF3, YTHDF3

1 Images
SDS-PAGE - Recombinant Human YTHDF3 protein (AB166020)
  • SDS-PAGE

Supplier Data

SDS-PAGE - Recombinant Human YTHDF3 protein (AB166020)

ab166020 on a 12.5% SDS-PAGE stained with Coomassie Blue.

Key facts

Expression system

Wheat germ

Tags

GST tag N-Terminus

Applications

ELISA, WB

applications

Biologically active

No

Accession

Q7Z739

Animal free

No

Carrier free

No

Species

Human

Storage buffer

pH: 8 Constituents: 0.79% Tris HCl, 0.31% Glutathione

storage-buffer

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "ELISA": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Sequence info

[{"sequence":"MSATSVDQRPKGQGNKVSVQNGSIHQKDAVNDDDFEPYLSSQTNQSNSYPPMSDPYMPSYYAPSIGFPYSLGEAAWSTAGDQPMPYLTTYGQMSNGEHHYIPDGVFSQPGALGNTPPFLGQHGFNFFPGNADFSTWGTSGSQGQSTQSSAYSSSYGYPPSSLGRAITDGQAGFGNDTLSKVPGISSIEQGMTGLKIGGDLTAAVTKTVGTALSSSGMTSIATNSVPPVSSAAPKPTSWAAIARKPAKPQPKLKPKGNVGIGGSAVPPPPIKHNMNIGTWDEKGSVVKAPPTQPVLPPQTIIQQPQPLIQPPPLVQSQLPQQQPQPPQPQQQQGPQPQAQPHQVQPQQQQLQNRWVAPRNRGAGFNQNNGAGSENFGLGVVPVSASPSSVEVHPVLEKLKAINNYNPKDFDWNLKNGRVFIIKSYSEDDIHRSIKYSIWCSTEHGNKRLDAAYRSLNGKGPLYLLFSVNGSGHFCGVAEMKSVVDYNAYAGVWSQDKWKGKFEVKWIFVKDVPNNQLRHIRLENNDNKPVTNSRDTQEVPLEKAKQVLKIIATFKHTTSIFDDFAHYEKRQEEEEAMRRERNRNKQ","proteinLength":"Full Length","predictedMolecularWeight":null,"actualMolecularWeight":null,"aminoAcidEnd":585,"aminoAcidStart":1,"nature":"Recombinant","expressionSystem":"Wheat germ","accessionNumber":"Q7Z739","tags":[{"tag":"GST","terminus":"N-Terminus"}]}]

Properties and storage information

Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-80°C
Appropriate long-term storage conditions
-80°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle
False

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The YTH domain family protein 3 (YTHDF3) is an m6A reader protein known also as YTH3 or YTHDF2-like protein 3. Its molecular weight is approximately 64 kDa. YTHDF3 plays a role in the recognition of N6-methyladenosine (m6A)-modified RNA an important post-transcriptional modification. It commonly expresses in various tissues including the brain liver and kidney indicating its involvement in multiple cellular processes. YTHDF3 binds to m6A-modified mRNA influencing the stability and translation of these molecules and interacts with other members of the YTH family.
Biological function summary

YTHDF3 facilitates the process of mRNA metabolism by participating in the regulation of mRNA translation and degradation. It functions as part of a dynamic complex with YTHDF1 and YTHDF2 coordinating the fate of m6A-modified mRNAs. YTHDF3 supports mRNA decay in synergy with YTHDF2 and enhances translation efficiency in cooperation with YTHDF1. This involvement in regulating gene expression at the post-transcriptional level equips cells to respond rapidly to various stimuli aligning gene expression with cellular needs.

Pathways

YTHDF3 significantly impacts RNA processing and metabolism pathways. YTHDF3 together with YTHDF1 and YTHDF2 modulates the m6A-mediated mRNA decay pathway. It holds functional significance in the cellular response to stress and adaptations in energy metabolism. YTHDF3 interacts closely with proteins such as IGF2BP1 alongside the YTHDF proteins which are critical in maintaining RNA stability and translation thereby illustrating its role across significant cellular pathways.

YTHDF3 has implications in cancer and neurodegenerative diseases. High YTHDF3 expression associates with various cancer types including gliomas and breast cancer where it can influence tumor growth and metastasis. In neurodegenerative diseases such as Alzheimer's disease YTHDF3 interacts with proteins like YTHDF1 and YTHDF2 affecting RNA metabolism in neurons contributing potentially to the pathology of these disorders. Through these interactions YTHDF3 could impact disease progression and outcomes making it a target of interest in therapeutic research.

Specifications

Form

Liquid

General info

Function

Specifically recognizes and binds N6-methyladenosine (m6A)-containing RNAs, and regulates their stability (PubMed : 28106072, PubMed : 28106076, PubMed : 28281539, PubMed : 32492408). M6A is a modification present at internal sites of mRNAs and some non-coding RNAs and plays a role in mRNA stability and processing (PubMed : 22575960, PubMed : 24284625, PubMed : 28106072, PubMed : 28281539, PubMed : 32492408). Acts as a regulator of mRNA stability by promoting degradation of m6A-containing mRNAs via interaction with the CCR4-NOT complex or PAN3 (PubMed : 32492408). The YTHDF paralogs (YTHDF1, YTHDF2 and YTHDF3) share m6A-containing mRNAs targets and act redundantly to mediate mRNA degradation and cellular differentiation (PubMed : 28106072, PubMed : 28106076, PubMed : 32492408). Acts as a negative regulator of type I interferon response by down-regulating interferon-stimulated genes (ISGs) expression : acts by binding to FOXO3 mRNAs (By similarity). Binds to FOXO3 mRNAs independently of METTL3-mediated m6A modification (By similarity). Can also act as a regulator of mRNA stability in cooperation with YTHDF2 by binding to m6A-containing mRNA and promoting their degradation (PubMed : 28106072). Recognizes and binds m6A-containing circular RNAs (circRNAs); circRNAs are generated through back-splicing of pre-mRNAs, a non-canonical splicing process promoted by dsRNA structures across circularizing exons (PubMed : 28281539). Promotes formation of phase-separated membraneless compartments, such as P-bodies or stress granules, by undergoing liquid-liquid phase separation upon binding to mRNAs containing multiple m6A-modified residues : polymethylated mRNAs act as a multivalent scaffold for the binding of YTHDF proteins, juxtaposing their disordered regions and thereby leading to phase separation (PubMed : 31292544, PubMed : 31388144, PubMed : 32451507). The resulting mRNA-YTHDF complexes then partition into different endogenous phase-separated membraneless compartments, such as P-bodies, stress granules or neuronal RNA granules (PubMed : 31292544). May also recognize and bind N1-methyladenosine (m1A)-containing mRNAs : inhibits trophoblast invasion by binding to m1A-methylated transcripts of IGF1R, promoting their degradation (PubMed : 32194978).. Has some antiviral activity against HIV-1 virus : incorporated into HIV-1 particles in a nucleocapsid-dependent manner and reduces viral infectivity in the next cycle of infection (PubMed : 32053707). May interfere with this early step of the viral life cycle by binding to N6-methyladenosine (m6A) modified sites on the HIV-1 RNA genome (PubMed : 32053707).

Sequence similarities

Belongs to the YTHDF family. YTHDF3 subfamily.

Post-translational modifications

(Microbial infection) Proteolytically cleaved by HIV-1 protease when incorporated into HIV-1 particles in a nucleocapsid-dependent-manner. Cleavage by HIV-1 protease probably ensures optimal infectivity of the mature virion.

Product protocols

Target data

Specifically recognizes and binds N6-methyladenosine (m6A)-containing RNAs, and regulates their stability (PubMed : 28106072, PubMed : 28106076, PubMed : 28281539, PubMed : 32492408). M6A is a modification present at internal sites of mRNAs and some non-coding RNAs and plays a role in mRNA stability and processing (PubMed : 22575960, PubMed : 24284625, PubMed : 28106072, PubMed : 28281539, PubMed : 32492408). Acts as a regulator of mRNA stability by promoting degradation of m6A-containing mRNAs via interaction with the CCR4-NOT complex or PAN3 (PubMed : 32492408). The YTHDF paralogs (YTHDF1, YTHDF2 and YTHDF3) share m6A-containing mRNAs targets and act redundantly to mediate mRNA degradation and cellular differentiation (PubMed : 28106072, PubMed : 28106076, PubMed : 32492408). Acts as a negative regulator of type I interferon response by down-regulating interferon-stimulated genes (ISGs) expression : acts by binding to FOXO3 mRNAs (By similarity). Binds to FOXO3 mRNAs independently of METTL3-mediated m6A modification (By similarity). Can also act as a regulator of mRNA stability in cooperation with YTHDF2 by binding to m6A-containing mRNA and promoting their degradation (PubMed : 28106072). Recognizes and binds m6A-containing circular RNAs (circRNAs); circRNAs are generated through back-splicing of pre-mRNAs, a non-canonical splicing process promoted by dsRNA structures across circularizing exons (PubMed : 28281539). Promotes formation of phase-separated membraneless compartments, such as P-bodies or stress granules, by undergoing liquid-liquid phase separation upon binding to mRNAs containing multiple m6A-modified residues : polymethylated mRNAs act as a multivalent scaffold for the binding of YTHDF proteins, juxtaposing their disordered regions and thereby leading to phase separation (PubMed : 31292544, PubMed : 31388144, PubMed : 32451507). The resulting mRNA-YTHDF complexes then partition into different endogenous phase-separated membraneless compartments, such as P-bodies, stress granules or neuronal RNA granules (PubMed : 31292544). May also recognize and bind N1-methyladenosine (m1A)-containing mRNAs : inhibits trophoblast invasion by binding to m1A-methylated transcripts of IGF1R, promoting their degradation (PubMed : 32194978).. Has some antiviral activity against HIV-1 virus : incorporated into HIV-1 particles in a nucleocapsid-dependent manner and reduces viral infectivity in the next cycle of infection (PubMed : 32053707). May interfere with this early step of the viral life cycle by binding to N6-methyladenosine (m6A) modified sites on the HIV-1 RNA genome (PubMed : 32053707).
See full target information YTHDF3

Publications (1)

Recent publications for all applications. Explore the full list and refine your search

Molecular cancer 22:202 PubMed38087322

2023

A positive feedback circuit driven by mA-modified circular RNA facilitates colorectal cancer liver metastasis.

Applications

Unspecified application

Species

Unspecified reactive species

Kaixuan Zeng,Jianhong Peng,Yue Xing,Linjie Zhang,Peishan Zeng,Weihao Li,Weili Zhang,Zhizhong Pan,Chi Zhou,Junzhong Lin
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com